HLS Operating Margin from 2010 to 2026
| HLS Stock | CAD 4.70 0.05 1.05% |
Check HLS Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among HLS Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 13.2 M, Interest Expense of 12.2 M or Total Revenue of 55.7 M, as well as many indicators such as Price To Sales Ratio of 1.19, Dividend Yield of 0.0102 or PTB Ratio of 0.73. HLS financial statements analysis is a perfect complement when working with HLS Therapeutics Valuation or Volatility modules.
HLS | Operating Margin |
Latest HLS Therapeutics' Operating Margin Growth Pattern
Below is the plot of the Operating Profit Margin of HLS Therapeutics over the last few years. It is HLS Therapeutics' Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in HLS Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (0.10) % | 10 Years Trend |
|
Operating Profit Margin |
| Timeline |
HLS Operating Margin Regression Statistics
| Arithmetic Mean | (0.01) | |
| Geometric Mean | 0.13 | |
| Coefficient Of Variation | (1,898) | |
| Mean Deviation | 0.15 | |
| Median | (0.09) | |
| Standard Deviation | 0.17 | |
| Sample Variance | 0.03 | |
| Range | 0.5288 | |
| R-Value | (0.71) | |
| Mean Square Error | 0.02 | |
| R-Squared | 0.50 | |
| Significance | 0 | |
| Slope | (0.02) | |
| Total Sum of Squares | 0.48 |
HLS Operating Margin History
About HLS Therapeutics Financial Statements
HLS Therapeutics investors utilize fundamental indicators, such as Operating Margin, to predict how HLS Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
HLS Therapeutics Inc., a specialty pharmaceutical company, focuses on acquiring and commercializing pharmaceutical products in the specialty central nervous system and cardiovascular markets. It has license agreement with Amarin Corporation plc to register, commercialize, and distribute Vascepa capsules in Canada. HLS THERAPEUTICS operates under Drug Manufacturers - Specialty Generic classification in Canada and is traded on Toronto Stock Exchange. It employs 46 people.
Other Information on Investing in HLS Stock
HLS Therapeutics financial ratios help investors to determine whether HLS Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in HLS with respect to the benefits of owning HLS Therapeutics security.